OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
OSL:PHO (4/25/2025, 7:00:00 PM)
56.5
+2.3 (+4.24%)
The current stock price of PHO.OL is 56.5 NOK. In the past month the price decreased by -3.25%. In the past year, price increased by 1.99%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 66.68 | 722.56B | ||
1LLY.MI | ELI LILLY & CO | 65.4 | 708.62B | ||
ZEG.DE | ASTRAZENECA PLC | 16.88 | 377.93B | ||
JNJ.DE | JOHNSON & JOHNSON | 15.27 | 324.94B | ||
NOV.DE | NOVO NORDISK A/S-B | 17.94 | 241.31B | ||
SNW.DE | SANOFI | 12.07 | 226.94B | ||
SAN.PA | SANOFI | 13.72 | 226.10B | ||
6MK.DE | MERCK & CO. INC. | 10.34 | 174.89B | ||
1MRKX.MI | MERCK & CO. INC. | 10.16 | 171.87B | ||
PFE.DE | PFIZER INC | 7.36 | 113.97B | ||
1PFE.MI | PFIZER INC | 7.17 | 111.02B | ||
BRM.DE | BRISTOL-MYERS SQUIBB CO | 41.5 | 84.44B |
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
PHOTOCURE ASA
Hoffsveien 4
Oslo OSLO NO
Employees: 102
Company Website: https://photocure.com/
Investor Relations: http://www.photocure.com/investors-hub
Phone: 4722062210
The current stock price of PHO.OL is 56.5 NOK. The price increased by 4.24% in the last trading session.
The exchange symbol of PHOTOCURE ASA is PHO and it is listed on the Euronext Oslo exchange.
PHO.OL stock is listed on the Euronext Oslo exchange.
8 analysts have analysed PHO.OL and the average price target is 83.13 NOK. This implies a price increase of 47.13% is expected in the next year compared to the current price of 56.5. Check the PHOTOCURE ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PHOTOCURE ASA (PHO.OL) has a market capitalization of 1.53B NOK. This makes PHO.OL a Small Cap stock.
PHOTOCURE ASA (PHO.OL) currently has 102 employees.
PHOTOCURE ASA (PHO.OL) has a support level at 56.03 and a resistance level at 56.59. Check the full technical report for a detailed analysis of PHO.OL support and resistance levels.
The Revenue of PHOTOCURE ASA (PHO.OL) is expected to grow by 14.63% in the next year. Check the estimates tab for more information on the PHO.OL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PHO.OL does not pay a dividend.
PHOTOCURE ASA (PHO.OL) will report earnings on 2025-05-08.
PHOTOCURE ASA (PHO.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
ChartMill assigns a technical rating of 4 / 10 to PHO.OL. When comparing the yearly performance of all stocks, PHO.OL turns out to be only a medium performer in the overall market: it outperformed 62.93% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to PHO.OL. No worries on liquidiy or solvency for PHO.OL as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months PHO.OL reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -1900% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -0.66% | ||
ROE | -0.96% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to PHO.OL. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 896.78% and a revenue growth 14.63% for PHO.OL